TLSA Tiziana Life Sciences Ltd
3,558
$0.6684
$0.0114
(1.68%)
| Watchers | 3,558 |
| 52-Wk Low | $0.41 |
| 52-Wk High | $1.27 |
| Market Cap | $130.08M |
| Volume | 57.00 |
| 52-Wk High | $1.27 |
| 52-Wk Low | $0.41 |
Tiziana Life Sciences to present at AD/PD of nasal anti-CD3 in Alzheimer'sThe Fly • 2 months ago
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Share to Feed
Data shows reduction of microglia activation and improvement in behavior in rodent models of Alzheimer's disease (AD) and Parkinson's disease (PD)Nasal anti-CD3 reduced hemorrhage and edema that...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) ( Tiziana or the Company ), a biotechnology company developing breakthrough neuro-immunomodulation therapies...
NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) ( Tiziana or the Company ), a biotechnology company developing breakthrough immunomodulation therapies, today...
NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) ( Tiziana or the Company ), a biotechnology company developing breakthrough immunomodulation therapies, today...
Tiziana Life Sciences files patent for foralumab combination therapy for obesity-associated inflammation...